03 / June / 2026 Daraxonrasib: the story of a drug that took 44 years to develop A New York Times report chronicles four decades of research culminating in the development of daraxonrasib, a drug that doubled the overall survival of patients with metastatic pancreatic cancer By Diogo Rodriguez
02 / June / 2026 Pancreatic cancer: Oral drug almost doubles survival in clinical trial Data presented at ASCO 2026 showed that daraxonrasib reduced the risk of death by 60% in patients with metastatic pancreatic cancer By Daniel Dieb
